

Bard1 Life Sciences Ltd

13:40 21 Mar 2018

BARD1 Life Sciences secures Israeli patent for unique lung cancer test

BARD1 Life Sciences Ltd (ASX:BD1) has been issued a patent in Israel for detecting BARD1 isoforms (proteins) in lung and colorectal cancer.

The company's proprietary technology platform, BARD1, is based on novel tumour markers with potential diagnostic and therapeutic applications across multiple cancers.

READ: Bard1 Life Sciences is one of the ASX's most active top performers today

The new patent protects the methods for detecting the presence of the specific BARD1 isoforms and methods for treating and/or preventing lung cancer and colorectal cancer.

Commercialising the company's diagnostic test

The BARD1 lung test is in development for the early detection of lung cancer.

The company is currently in discussions with a number of contract laboratory organisations to transfer its work to date to a commercial platform.

This will enable the BARD1 tests to be performed by most hospital and independent clinical laboratories around the world.

Leading cause of cancer death in Australia

Lung cancer is the fifth most common cancer and the leading cause of cancer death in Australia.

The Australian Institute of Health and Welfare (AIHW) estimates that there will be 12,741 new cases of lung cancer diagnosed (9.2% of all new cancers diagnosed) and 9,198 deaths from lung cancer (18.9% of all cancer deaths) in Australia in 2018.

Early detection of lung cancer can save people's lives

Lung cancer is often diagnosed at a later stage after it has spread to other parts of the body, resulting in a 15.8% chance of survival after 5-years in Australia.


Early detection of lung cancer has the potential to save people's lives by enabling earlier treatment when it is potentially curable.

There is currently no approved blood test available for screening of lung cancer in people without symptoms.

Price: A\$0.03

Market Cap: A\$41.02M

1 Year Share Price Graph



Share Information

Code: BD1

Listing: ASX

52 week High Low
A\$0.07 A\$0.01

Sector: Pharma & Biotech

Website: www.bard1.com

Company Synopsis:

Bard1 Life Sciences Ltd (ASX:BD1) is listed on the Australian Securities Exchange.

Author:

Proactive Investors Australia

+61 (0)2 9280 0700

action@proactiveinvestors.com.au

BARD1's patent portfolio comprises five patent families with multiple granted and pending patents across key marketplaces including the US, Europe and Japan.

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +61 (0)2 9280 0700 action@proactiveinvestors.com.au

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.